Dossier assessment
Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
| Children and adolescents aged 6 to < 18 years (body weight of at least 17kg) with chronic hepatitis C |
Result of dossier assessment:
| Patients aged 6 to 11 years with genotype 1 or 3: hint of non-quantifiable added benefit. Older patients and other genotypes: added benefit not proven |
Project details
- Project no.
- A20-86
- Commission
- Commission awarded on 22.09.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V
Status: Commission completed
-
Dossier assessment
Sofosbuvir/velpatasvir (chronic hepatitis C in children 3 to < 6 years of age) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed